Theme: {CME-CPD Accreditations Available} Emerging Advances in Gastro Cancer

GASTRO CANCER 2023
Tentative Program

Renowned Speakers

GASTRO CANCER 2023

In the last few decades, diagnostic and therapeutic advances in Gastrointestinal Cancer have been notable. However, because of contemporary eating and living practices, many fields continue to provide difficulties. To explore more in-depth research findings and recent innovations join us at the “22nd World Congress on Gastrointestinal Cancer” which is scheduled on November 13-14, 2023 at the city of hidden gems Dublin, Ireland and share your thoughts on the “Emerging Advances in Gastro Cancer” which is designed as the theme for this Gastro Cancer Conference. Stay united with the Oncology meeting to have a stance on major future innovations in some hot clinical topics in Gastro Cancer, as well as the current pitfalls and the grey zones.


Target Audience

  • Gastroenterologists
  •  Hepatologists
  • Colorectal surgeons
  • Physician Assistants
  • Nurse Practitioners
  • Clinical Researchers & Scientists
  • Public Health Professionals
  • Pathologists
  • Medical Practitioners
  • Professors
  • General and acute medicine consultants and trainees
  • Gastro oncology nursing staff
  • Researchers
  • Scientists
  • Society for Gastrointestinal Oncology
  • AGA Institute Council Gastrointestinal Oncology Section (GIONC)
  • Surgeons
  • Radiologists
  • General scientists
  • Young investigators
  • Nurses
  • Pharmacists with an interest in GI oncology.

The benefit of the Association for Collaborators

  • Nobody in the world has such high levels of demand for medical treatment, making it the most straightforward platform for social commentary.
  • Creating long-lasting peer relationships.
  • Your organization's logo, branding and marketing materials, promotional content, and our webinar banner will all work to boost your subscriptions and members by 40%.
  •  The association will be significantly impacted by the exposure of our event to your company's listing in the Global Business Forum.
  • The representatives can connect with important webinar attendees to update their knowledge and comprehension of your company and services.
  • Information will be included in gastrooncology prevention promotional materials such as posters, booklets, pamphlets, and services that will be sent to hospitals, universities, the general public, and researchers.

      Track 1: Gastrointestinal Disorders

      Track 2: Gastrointestinal Cancer

      Track 3: Gastrointestinal Oncology

      Track 4: Gastroenterology

      Track 5:  Gastrointestinal Immunology

      Track 6: Nutrition in Cancer

     Track 7: Irritable Bowel Syndrome

      Track 8: Gastrointestinal Pathology

      Track 9: Clinical Advances in Liver Diseases

      Track 10: Liver Cirrhosis

      Track 11:  Hepato Radiology

      Track 12: Digestive Disorders

      Track 13: Gastroesophageal Reflux Malady

      Track 14: Gastrointestinal Radiology

      Track 15: Microbiota and Diseases

Track 16: Liver Diseases and Hepatitis

Track 17: Gallbladder and Biliary Tract Diseases

Track 18: Gastrointestinal Endoscopy

Track 19: Gastrointestinal Pharmacology

Track 20: Gastrointestinal Therapeutics

Track 21: Neuro Gastroenterology

Track 22: Covid-19 and GI Cancer Management

 

  • Describe the current practises for treating gastrointestinal (GI) cancers.
  • Analyze clinical trial data that could affect GI oncology therapy choices.
  • Employ multimodal strategies in the treatment of GI cancers.

According to World Cancer Research Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012. Gastric cancer was the fifth-most common type of cancer in the world. This epidemic has forced researchers, doctors, and governments to adopt various therapeutic treatments related to gastric cancer. An increase in investment by the companies and regulations by the government encouraging research on the same has provided significant momentum to the growth of the gastric cancer therapeutics market. This trend is likely to persist throughout the forecast period, since the number of cases of gastric cancer around the globe is rising at an alarming rate.


 

According to National Cancer Institute, there were a projected 79,843 individuals with stomach cancer in the U.S. alone, in 2013. According to the same report, gastric cancer represented a whopping 1.6% of the new cancer cases reported in the U.S. According to the National Cancer Institute, an estimated 26,370 new cases of the disease were reported, leading to 10,730 deaths in the U.S. in 2016. Rising incidence of stomach cancer in the U.S., positions it as a high growth market for gastric cancer therapeutics.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 13-14, 2023
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed
Poster Opportunity Closed Click Here to View